APO-CONEST TAB 2.5MG 2.5 MG
CONJUGATED ESTROGENS : 2.5 MG · DIN 00798193 · APOTEX INC
Health Canada status: CANCELLED POST MARKET
What is APO-CONEST TAB 2.5MG?
APO-CONEST TAB 2.5MG 2.5 MG contains CONJUGATED ESTROGENS : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 00798193, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-Oct-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00798193 |
|---|---|
| Brand name | APO-CONEST TAB 2.5MG |
| Generic / active ingredient | CONJUGATED ESTROGENS : 2.5 MG |
| Manufacturer | APOTEX INC |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03CA57 CONJUGATED ESTROGENS |
| AHFS class | 68:16.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-Oct-2009 |
| Original market date | 1994-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code G03CA57 CONJUGATED ESTROGENS. 4 of 33 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PREMARIN | 0.3 MG | TABLET (EXTENDED-RELEASE) | PFIZER CANADA ULC | MARKETED | DIN 02414678 |
| PREMARIN | 1.25 MG | TABLET (EXTENDED-RELEASE) | PFIZER CANADA ULC | MARKETED | DIN 02414694 |
| PREMARIN INTRAVENOUS | 25 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02043386 |
| PREMARIN VAGINAL CREAM | 0.625 MG | Cream | PFIZER CANADA ULC | MARKETED | DIN 02043440 |
| APO-CONEST TAB 0.3MG | 0.3 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798231 |
| APO-CONEST TAB 0.625MG | 0.625 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798223 |
| APO-CONEST TAB 0.9MG | 0.9 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798215 |
| APO-CONEST TAB 1.25MG | 1.25 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798207 |
| C.E.S. | 0.625 MG | TABLET | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00265470 |
| C.E.S. TABLETS | 0.3 MG | TABLET | VALEANT CANADA LP / VALEANT CANADA S.E.C. | CANCELLED POST MARKET | DIN 02230891 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.